Osteoarthritis drug developer Paradigm says its purchase of an oral drug candidate won’t distract it from its key phase III knee trial. In a heavily back-ended deal, Paradigm will pay as much as $16.5 ...
The book “Cyber Persistence Theory” by Michael Fischerkeller, Emily Goldman, and Richard Harknett suggests a paradigm shift of the strategic environment shaped by the Cold War and twenty years of ...